Marshall Wace

Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Sammaan Capital is a mortgage-focused non-banking financial company based in India, founded in 2000. The company specializes in providing a range of financial services, including home loans, loans for non-resident Indians, and loans against properties, all offered at competitive interest rates. Catering to both salaried and self-employed individuals, Sammaan Capital aims to facilitate quick access to funding for various purposes such as construction, renovation, and the purchase of residential properties, including apartments, flats, and bungalows. Additionally, the company extends its lending services to cooperative societies, associations, companies, builders, developers, and contractors, ensuring a diverse clientele while conducting all operations within India.

Aviceda Therapeutics is a late-stage pre-clinical biotechnology company focused on developing innovative therapies for glyco-immune diseases. The company leverages glycobiology and a proprietary cell-based high-throughput screening platform to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda’s therapeutic pipeline includes a range of products aimed at various conditions, such as dry eye, diabetic retinopathy, retinoblastoma, and other diseases in the fields of oncology, neurology, and fibrosis. The company’s approach combines advanced biological insights with cutting-edge nanoparticle technology, enabling the development of targeted treatments designed to improve patient outcomes.

35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics to address diseases with high unmet medical needs, particularly pulmonary hypertension and musculoskeletal disorders. The company leverages its expertise in protein engineering and its understanding of transforming growth factor-beta (TGF-beta) structure-function relationships to create highly potent ligand traps. These developments aim to enhance treatment options for patients suffering from cardio-pulmonary and metabolic diseases. By combining advanced scientific knowledge with a commitment to addressing critical health challenges, 35Pharma seeks to contribute significantly to the biopharmaceutical landscape.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Inquis Medical is a company focused on developing innovative thrombectomy technology aimed at enhancing the management of venous thromboembolic diseases. The company’s medical devices are designed to address unmet clinical needs and improve the standard of care in this field. By offering an efficient single-pass thrombectomy solution with minimal blood loss, Inquis Medical aims to provide healthcare professionals with advanced tools that can significantly impact patient outcomes and long-term health management.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on revolutionizing drug delivery to enhance patient experiences. Founded in 2016, Elektrofi specializes in a formulation system capable of processing a broad spectrum of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. The company's technology aims to improve subcutaneous administration, enabling drug manufacturers to create innovative therapies that offer patients greater control over how they receive life-changing medicines.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease, particularly targeting secondary hyperparathyroidism (SHPT). SHPT is a condition characterized by the overactivity of the parathyroid glands, resulting from diseases outside of these glands, leading to excessive production of parathyroid hormone (PTH). The company's lead product, upacicalcet, is a novel calcimimetic designed to improve treatment outcomes for hemodialysis patients by mimicking calcium's effects on tissues through the activation of calcium-sensing receptors found in various human organs. Pathalys aims to address significant unmet medical needs in the management of SHPT, ultimately enhancing the quality of care for patients with end-stage chronic kidney disease.

Human Interest is a retirement plan provider based in San Francisco, California, founded in 2015 by Paul Sawaya and Roger Lee. The company specializes in making it easy for small and medium-sized businesses to offer retirement savings plans to their employees. Human Interest has developed an end-to-end technology platform that addresses administrative and compliance challenges, providing affordable and straightforward employee retirement plans. This platform automatically creates employee accounts and syncs deductions with payroll providers, while also offering personalized investment advice. Through these services, Human Interest has assisted thousands of businesses across America in providing retirement accounts to their employees.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Mind Medicine Inc. is a biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies aimed at addressing addiction and mental health issues. Headquartered in New York, the company is building a diverse drug development pipeline that includes innovative treatments derived from psychedelic substances such as Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative known as 18-MC. Founded in 2010 by JR Rahn, Scott Freeman, Leonard Latchman, and Stephen L. Hurst, MindMed is actively engaged in forming collaborations and conducting clinical trials to further explore the therapeutic potential of these substances in treating brain health disorders.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Areteia Therapeutics is a biotechnology company focused on developing innovative treatments for asthma, particularly eosinophilic asthma. Spun out from Knopp in Pennsylvania, the company aims to empower asthma patients by providing them with better control over their condition. Areteia is advancing an oral drug candidate that works by inhibiting the maturation of eosinophils, which are immune cells that can damage the airways and exacerbate asthma symptoms. The drug has shown promise in clinical trials, with results indicating its potential to reduce blood eosinophil counts, a key marker associated with improved lung function. This breakthrough could offer a much-needed accessible treatment option for millions of individuals suffering from this severe form of asthma, allowing them to manage their disease more effectively and improve their quality of life.

OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

BlueWhale Bio is a spinout from the University of Pennsylvania focused on advancing cell-based therapies through innovative manufacturing solutions. The company develops cell drugs aimed at addressing challenges in gene therapy manufacturing, particularly in the context of cancer treatment. By specializing in cell therapy, BlueWhale Bio seeks to enable patients to access effective cancer treatment plans, thereby contributing to the broader field of regenerative medicine and improving therapeutic outcomes for individuals battling cancer.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on the research, development, and commercialization of innovative medicines for infectious diseases. Founded in 2017, the company aims to address significant unmet medical needs through its development of novel therapeutics. Its lead product candidate, epetraborole, is a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. AN2 Therapeutics is committed to leveraging advanced biomedical expertise to create transformative solutions for patients dealing with serious and rare infectious diseases. The company has also established a strategic partnership with Brii Biosciences to enhance its development efforts.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

InspireMD, Inc. is a medical device company based in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology aimed at treating vascular and coronary diseases. The company offers two primary products: the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, used in patients with acute coronary syndromes and saphenous vein graft interventions. InspireMD is also working on the NGuard neurovascular flow diverter, which aims to divert blood flow from cerebral aneurysms to enhance patient outcomes. The company's products are marketed through local distributors in various regions, including Europe, Latin America, the Middle East, and Asia.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Thunes is a global B2B payment infrastructure platform established in 2016, specializing in cross-border payment solutions. It facilitates seamless fund transfers between various payment systems, catering to a diverse range of clients, including major players in the gig economy and fintech sectors. The platform enables businesses and consumers to send and receive payments in 80 currencies across 132 countries, supporting 300 payment methods. Thunes offers a suite of services including remittance processing, mass payouts, virtual accounts, and payment collection, utilizing application programming interfaces (APIs) to enhance accessibility and reduce transaction costs. In April 2022, the company expanded its capabilities by acquiring a controlling stake in Tookitaki, a compliance platform that strengthens its anti-money laundering and fraud prevention measures. Headquartered in Singapore, Thunes operates regional offices in key global cities such as London, Paris, and Dubai, positioning itself as a vital player in the international payment landscape.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.

TRM Labs Inc. is a blockchain intelligence company that provides a platform focused on token relationship management, utilizing machine learning to assist clients in managing customer relationships and detecting suspicious activities. The platform offers solutions for on-chain anti-money laundering (AML) compliance, including customer due diligence, transaction monitoring, and relationship management specifically tailored for digital asset firms. Additionally, TRM Labs develops enterprise applications and tools that enable organizations to launch blockchain-based products aimed at identifying fraudulent activities such as money laundering and market manipulation. Founded in 2017 and headquartered in San Francisco, California, the company serves a diverse clientele, including financial institutions, cryptocurrency businesses, and government agencies, and has established partnerships with notable organizations such as PayPal, Visa, and federal agencies. TRM Labs is committed to enhancing the safety of the financial ecosystem through advanced data engineering and threat intelligence, backed by a team of experts with extensive experience in law enforcement and technology.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Neurolens is a company founded in 2012 and based in Costa Mesa, California, specializing in innovative vision solutions. It develops prescription lenses that incorporate a contoured prism to enhance eye alignment, addressing common issues such as headaches, neck or shoulder pain, and eyestrain that often arise from prolonged use of digital devices, reading, or detailed tasks. Neurolens also offers a vision measurement device system that utilizes an advanced eye-tracking technology to detect even minor misalignments in the eyes. This capability enables effective treatment for patients suffering from chronic headaches and other related symptoms, making Neurolens a key player in the vision correction market.

21Shares AG, established in 2018 and headquartered in Zug, Switzerland, specializes in developing and managing crypto exchange-traded products. The company offers a range of index-based products, including the 21Shares Crypto Basket Index (HODL5), which provides diversified exposure to the top five cryptocurrencies, listed on the Swiss Stock Exchange. 21Shares aims to make cryptocurrency investing accessible, secure, and regulated, enabling investors to buy, sell, and short cryptocurrencies through existing bank and brokerage accounts. The company's issuance platform, Onyx, is used for issuing and operating cryptocurrency ETPs worldwide.

21.co is a cryptocurrency company providing access to crypto through simple and easy-to-use products. 21.co is the parent company of 21Shares, the world’s largest issuer of cryptocurrency exchange-traded products (ETPs) – which is powered by Onyx, a proprietary technology platform used to issue and operate cryptocurrency ETPs for 21Shares and third parties – in addition to Amun, a token provider focused on making the Defi world more accessible. The company was founded in 2018 by Hany Rashwan and Ophelia Snyder. 21.co is registered in Zug, Switzerland with offices in Zurich and New York.

Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on revolutionizing drug delivery to enhance patient experiences. Founded in 2016, Elektrofi specializes in a formulation system capable of processing a broad spectrum of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. The company's technology aims to improve subcutaneous administration, enabling drug manufacturers to create innovative therapies that offer patients greater control over how they receive life-changing medicines.

Turtlemint is an online insurance platform based in Mumbai, Maharashtra, India, that simplifies the process of buying and managing insurance policies. Founded in 2015, the company aims to make insurance accessible and understandable by demystifying complex jargon and providing user-friendly tools. Turtlemint offers a range of insurance products, including car, bike, health, and term life insurance, allowing customers to search, compare, and purchase policies entirely online with just a few clicks. The platform leverages proprietary algorithms and data analytics to provide personalized recommendations, while also offering a network of offline facilitators to assist with the purchase and claims process. This comprehensive approach enables clients to select the right insurance schemes tailored to their needs.

Circle is a financial technology firm established in 2013 by Jeremy Allaire and Sean Neville, headquartered in Boston, with additional offices in New York, San Francisco, Dublin, London, and Hong Kong. The company leverages blockchain technology to facilitate payments and e-commerce through stablecoins and its Circle Pay platform, streamlining the process of sending money. Circle offers a range of services, including Circle Invest, which allows users to buy and sell cryptocurrency assets, and Circle Trade, which provides over-the-counter trading services with access to one of the largest global liquidity pools for digital asset trading, averaging $2 billion in monthly volume. Backed by prominent investors such as Goldman Sachs and Accel Partners, Circle positions itself as a key player in the global internet finance sector, focused on integrating crypto assets into mainstream financial applications.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Lukka, Inc. is a blockchain-native technology company based in New York that specializes in providing middle and back office solutions for the crypto-asset ecosystem. Founded in 2014 and rebranded from Libra Services, Inc. in 2019, Lukka focuses on managing and processing complex blockchain and cryptocurrency data to enhance accessibility and utility for businesses. Its offerings include LukkaTax, which simplifies tax calculations and compliance for cryptocurrency transactions, and LukkaCrypto Office, a back-office solution for managing crypto assets that features pricing, valuation, and reporting capabilities. Additionally, Lukka Reference Data ensures the consistency and accuracy of crypto asset data for enterprise applications. By automating and optimizing accounting, audit, and tax processes, Lukka delivers real-time visibility into crypto transaction activity, catering to the reporting and compliance needs of funds, fund administrators, exchanges, and enterprises.

Accelerant Holdings Ltd. is a managing general agent (MGA) based in London, United Kingdom, founded in 2018. The company specializes in providing wholesale insurance underwriting services primarily for small and medium-sized enterprises (SMEs). As an insurtech, Accelerant leverages advanced data analytics and technology to enhance its risk exchange platform, enabling underwriters to access superior insights and capacity commitments. The firm's specialty portfolio is well-diversified, minimizing exposure to catastrophe and systemic risks. Additionally, Accelerant has established a carefully selected network of underwriting teams to ensure high-quality service delivery, earning it an excellent AM Best A- rating.

Tipalti, Inc., established in 2010, specializes in accounts payable automation and global mass payments. Headquartered in San Mateo, California, with an additional office in Israel, the company offers a comprehensive software solution that streamlines and automates the process of paying suppliers, partners, and publishers worldwide. Tipalti's platform covers all aspects of the payables workflow, including supplier onboarding, invoice processing, global funds disbursement, tax compliance, and payment reconciliation. By utilizing Tipalti, businesses can significantly reduce their supplier payment workload, strengthen financial controls, ensure regulatory compliance, and improve partner payment experiences, enabling them to focus on strategic growth.

TRM Labs Inc. is a blockchain intelligence company that provides a platform focused on token relationship management, utilizing machine learning to assist clients in managing customer relationships and detecting suspicious activities. The platform offers solutions for on-chain anti-money laundering (AML) compliance, including customer due diligence, transaction monitoring, and relationship management specifically tailored for digital asset firms. Additionally, TRM Labs develops enterprise applications and tools that enable organizations to launch blockchain-based products aimed at identifying fraudulent activities such as money laundering and market manipulation. Founded in 2017 and headquartered in San Francisco, California, the company serves a diverse clientele, including financial institutions, cryptocurrency businesses, and government agencies, and has established partnerships with notable organizations such as PayPal, Visa, and federal agencies. TRM Labs is committed to enhancing the safety of the financial ecosystem through advanced data engineering and threat intelligence, backed by a team of experts with extensive experience in law enforcement and technology.

ConsenSys, established in 2015 by Ethereum co-founder Joseph Lubin, is a leading Ethereum software company focused on Web3. It offers a suite of products, including Infura, Quorum, Truffle, Codefi, MetaMask, and Diligence, which serve millions of users and support billions of blockchain-based queries. ConsenSys enables developers and enterprises worldwide to build next-generation applications and access the decentralized web, fostering business adoption and growth of the Ethereum ecosystem. Additionally, ConsenSys Academy, its educational arm, bridges the Ethereum knowledge gap globally for ecosystem development.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Vayana Network is a financing network that facilitates electronic trade transactions between businesses and their trade partners. It enables companies to efficiently manage their receivables and payables by connecting them with banks and financial institutions for financing options. Through its online lending platform, Vayana Network provides working capital finance specifically designed for small and medium enterprises, allowing them to access short-term business loans to support growth. The company also offers a Commercial Card solution in collaboration with MasterCard and various banks, enhancing payable financing options for its clients. By streamlining the trade financing process, Vayana Network aims to empower businesses in managing their financial operations more effectively.

CRED is a members-only application that incentivizes users by offering exclusive rewards for timely credit card bill payments. The platform promotes financial responsibility by encouraging users to maintain good credit scores while rewarding them with various offers and discounts on shopping, health services, and other expenditures. CRED prioritizes the protection of user data through stringent security processes and compliance with regulatory standards, ensuring transparency and opt-in consent for data usage. By facilitating on-time credit card payments, CRED not only helps users manage their finances better but also enhances their overall spending experience with valuable rewards.

Varo Money, Inc. is a digital bank based in San Francisco, California, that offers a range of online banking products and services, including bank and savings accounts, checking accounts, and overdraft protection. Established in 2015 and known for being the only U.S. consumer fintech with a national bank charter, Varo aims to serve as a comprehensive banking partner for millions of Americans, especially those seeking better financial solutions. The company combines fintech innovation with the security of a chartered bank, providing tools and insights to enhance financial resilience for its customers. Varo's platform also includes features such as spending analysis, real-time budgeting, cash flow forecasts, direct deposits, and online bill payments, all designed to empower users to make informed financial decisions and improve their overall financial well-being.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company based in Campbell, California, focused on developing innovative therapies for gastrointestinal disorders. Incorporated in 2017, the company specializes in creating products that address unmet medical needs related to the enteric nervous system. One of its lead products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx aims to provide effective solutions for functional and motility gastrointestinal disorders, targeting issues related to gut contractions, sensation, and the brain-gut axis, thereby addressing significant patient needs and alleviating disease burdens.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Circle is a financial technology firm established in 2013 by Jeremy Allaire and Sean Neville, headquartered in Boston, with additional offices in New York, San Francisco, Dublin, London, and Hong Kong. The company leverages blockchain technology to facilitate payments and e-commerce through stablecoins and its Circle Pay platform, streamlining the process of sending money. Circle offers a range of services, including Circle Invest, which allows users to buy and sell cryptocurrency assets, and Circle Trade, which provides over-the-counter trading services with access to one of the largest global liquidity pools for digital asset trading, averaging $2 billion in monthly volume. Backed by prominent investors such as Goldman Sachs and Accel Partners, Circle positions itself as a key player in the global internet finance sector, focused on integrating crypto assets into mainstream financial applications.

Pine Labs is a technology and financial solutions provider focused on enhancing merchant operations and increasing revenue. The company offers a comprehensive platform that facilitates both online and offline transactions, enabling retailers to connect with financial institutions and consumer brands efficiently. Its services include processing easy monthly installment transactions, delivering customer insights for targeted sales, and simplifying payment acceptance. Pine Labs supports over 350,000 POS terminals across 3,700 cities in India and Malaysia, catering to more than 100,000 merchants in diverse sectors such as electronics, food and beverage, fashion, and airlines. The company collaborates with 15 major banks and 7 financial institutions, ensuring a robust ecosystem for retailers to engage and retain customers while minimizing operational complexities and risks.

Forge Biologics, Inc. is a contract development and manufacturing organization (CDMO) specializing in gene therapies and genetic medicines. Founded in 2019 and based in Columbus, Ohio, the company focuses on developing and manufacturing therapeutics, particularly for viral vector gene therapies aimed at treating genetic diseases. Notably, it offers a novel approach combining adeno-associated virus (AAV) and umbilical cord transplant to address infantile Krabbe disease, a severe neurodegenerative disorder. Additionally, Forge Biologics collaborates with scientists, physicians, biotech and pharmaceutical companies, and patient groups to facilitate the progression of gene therapy programs from preclinical development through to clinical and commercial-scale manufacturing. The company is committed to enabling access to transformative medicines for patients suffering from rare genetic diseases.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

International Airlines Group (IAG) is one of the largest airline groups globally, primarily engaged in the transportation of passengers and cargo. It operates multiple well-known subsidiaries, including British Airways, Iberia, Vueling, and Aer Lingus, which maintain their distinct brands while benefiting from the group's combined resources. IAG's main airport hubs are located in London, Madrid, Barcelona, and Dublin, allowing it to enhance its global presence. The group's revenue is predominantly generated from the United Kingdom, with significant contributions also from Spain, the United States, and other international markets. Each airline within the group is managed as a separate operating company, facilitating tailored strategies and resource allocation.

LGI Homes, Inc. is a homebuilder based in The Woodlands, Texas, specializing in the design, construction, and sale of new homes across the United States. Founded in 2003, the company offers a range of residential properties, including entry-level homes, move-up homes, and luxury series homes marketed under the Terrata Homes brand. LGI Homes operates 113 communities across various states, including Texas, Arizona, Florida, and Georgia, among others. The company provides a selection of floor plans and customizable features, such as granite countertops and ceramic tile flooring, catering to diverse customer needs. With a focus on delivering quality homes at competitive prices, LGI Homes serves a wide array of markets through its multiple operating segments.